Betta Pharmaceuticals

Pre-IPO Betta Pharmaceuticals - Lack of Staying Power

Equity Capital Markets
143 Views, 13 Jan 2022 09:22
EXECUTIVE SUMMARY
  • If the R&D pipeline projects are not recognized by international capital,the main reason could be either the product development progress is lagging behind or the projects are not good enough.
  • The real innovative drugs would not be affected by generics that easily, and are to overturn the size of the old drug market.
  • The real risk of Betta would be revealed in the next few years as VBP promotes. So, we are conservative about the Company’s outlook at the current stage.
detail (5-minute read)
WHAT’S TRENDING
logo
Logo
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in ... 

x